• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov28
Citi initiates coverage of Nektar Therapeutics with a Buy rating and sets a $102 price target
13:02
Nov17
William Blair Maintains Hold Rating on NKTR
23:26
Nov11
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics
12:02
Nov7
Nektar Therapeutics released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 33.43 M and actual EPS of USD -8.4458
00:00
Nektar Therapeutics released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 11.79 M (forecast USD 10.2 M), actual EPS USD -1.8748 (forecast USD -2.6065)
00:00
Oct30
Nektar Therapeutics to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast Revenue USD 10.2 M, EPS USD -2.6065
00:51

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 11.79 M, Net Income -35.52 M, EPS -1.8748

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 11.18 M, Net Income -41.59 M, EPS -2.9525

Jun9
Reverse Stock Split(EST)

1-for-15 Reverse Stock Split

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
ASTX
46.070
+36.50%
+12.320
ABLV
0.9715
+34.87%
+0.251
View More